Colleen E. Casey

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma”.

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0684

N/A

0DataRank · unranked

4 citations

Michael P. East, Timothy J. Stuhlmiller, Gabriela M. Witek, Alvin Farrel, Steven Pastor +13 more

A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Nature Communications(2025)10.1038/s41467-025-62979-1

N/A

0DataRank · unranked

4 citations

Smita Matkar, Christina Acholla, Colleen E. Casey, Grant Li, Martina Mazzeschi +28 more

Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma.

UNC Libraries(2025)10.17615/pbz0-mn14

N/A

0DataRank · unranked

0 citations

Mark Gerelus, Michael P. East, Alvin Farrel, Steven Pastor, John M. Maris +13 more